Bone anabolic agents fob osteoporosis treatment;Agentes anabólicos óseos para el tratamiento de osteoporosis

Endocrinologia y Nutricion

Volumn 51, Issue 9, 2004, Pages 512-523

  Quesada, J M ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Fluoride; Growth hormone; Insulin like growth factor I; Osteoporosis; Parathyroid hormone; Statins; Strontiume

Indexed keywords

ANABOLIC AGENT; BONE MORPHOGENETIC PROTEIN 2; CALCIUM; COMPACTIN; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR; FLUINDOSTATIN; FLUORINE; GROWTH HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN; MEVINOLIN; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; PARATHYROID HORMONE DERIVATIVE; PARATHYROID HORMONE RECEPTOR; PARATHYROID HORMONE[1-31]; PARATHYROID HORMONE[1-34]; PROTEIN BCL X; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SIMVASTATIN; SOMATOMEDIN C; STRONTIUM; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D;

DRUG EFFICACY; DRUG INDICATION; FOOD AND DRUG ADMINISTRATION; HEADACHE; HIP FRACTURE; HORMONAL THERAPY; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; HYPERURICEMIA; MYALGIA; NAUSEA; NEPHROLITHIASIS; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; REVIEW; SPINE FRACTURE;

EID: 11144338761     PISSN: 15750922     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1575-0922(04)74658-6     Document Type: Review

References (90)

1. NIH Consensus Statement. Osteoporosis prevention, diagnosis, and therapy 2000;17:1-36.
2. Grupo de Trabajo de la Sociedad Española de Investigaciones Óseas y Metabolismo Mineral (SEIOMM). Osteoporosis postmenopá usica. Guía de práctica clínica. Rev Clin Esp 2003;203:496-506.
3. Cummings SR, Melton LJ III. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002;359:1761-7.
4. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999;104:439-46.
5. Seeman E. Osteoporosis. Pathogenesis of bone fragility in women and men. Lancet 2002;359:1841-50.
6. Currey JD. The mechanical consequences of the variation in the mineral content of bone. J Biomech 1969;2:1-11.
7. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002;359:2018-26.
8. Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science 2002;289:1508-14.
9. Hodsman AB, Hanley DA, Watson DA, Fraher LJ. Parathyroid hormone. En: Bilezikian J, Raisz L, Rodan G, editors. Principles of bone biology. San Diego: Academic Press, 2002; p. 1305-24.
10. Carverzasio J, Palmer G, Bonjour JP, Fluoride mode of action. Bone 1998;22:585-603.
11. Riggs BL, Hodgson SF, O'Fallon WM, Chao EY, Wahner HW, Muhs JM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990;322:802-9.
12. Pak CY, Zerwekh JE, Antich PP, Bell NH, Singer FR. Slow-release sodium fluoride in osteoporosis. J Bone Miner Res 1996;11:561-4.
13. Gutteridge DH, Stewart GO, Prince RL, Price RI, Retallack RW, Dhaliwal SS, et al. A randomised trial of sodium fluoride and estrogen in post menopausal osteoporotic vertebral fractures. Osteoporosis Int 2002;13:158-70.
14. Ringe JD, Rovati LC. Treatment of osteoporosis in men with fluoride alone or in combination with bisphosphonates. Calcif Tissue Int 2001;69:252-5.
15. Reginster JY, Meurmans L, Zegels B, Rovati LC, Minne HW, Giacovelli G, et al. The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial. Ann Intern Med 1998;129:1-8.
16. Haguenauer D, Welch V, Shea B, Tugwell P, Wells G. Fluoride for treating postmenopausal osteoporosis. Cochrane Database Syst Rev 2000;4:CD002825.
17. Rosen CJ, Bilezikian JP. Anabolic Therapy for osteoporosis. J Clin Endocrinol Metab 2001;86:957-64.
18. Bauer DC, Rosen CJ, Cauley J, et al. Low serum IGF-1 but not IGFBP-3 predicts hip and spine fracture: the study of osteoporotic fracture. J Bone Miner Res 1998;23:S561.
19. Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY Goldberg AF, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990;323:1-6.
20. Holloway L, Kohlmeier L, Kent K, Marcus R. Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women. J Clin Endocrinol Metab 1997;82:1111-7.
21. Bauer E, Aub J, Albright F. Studies of calcium and phosphorus metabolism. A study of the bone trabeculae as a readily available reserve supply of calcium. J Exp Med 1929;49:145-62.
22. Péhu M, Policard A, Dufort A. L'Ostéopétrose ou maladie des os marmoréens. Presse Méd 1931;53:999-1003.
23. Selye H. On the stimulation of new bone formation with parathyroid extract and irradiated ergosterol. Endocrinology 1932;16:547-58.
24. Pugsley LI, Selye H. The histological changes in the bone responsible for the action of parathyroid hormone on the calcium metabolism of the rat. J Physiol 1933;79:113-7.
25. Tregear GW, Van Rietschoten J, Greene E, Keutmann HT, Niall HD, Reit B, et al. Bovine parathyroid hormone: minimum chain length of synthetic peptide required for biological activity. Endocrinology 1974;93:1349-53.
26. Reeve J, Hesp R, Williams D, Hulme P, Klenerman L, Zanelli S, et al. Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis. Lancet 1976;1:1035-8.
27. Reeve J, Tregear GW, Parsons JA. Preliminary trial of low doses of human parathyroid hormone 1-34 peptide in treatment of osteoporosis. Calcif Tissue 1976;21:469-77.
28. Reeve J, Meunier PJ, Parsons JA, Bernat M, Bijvoet OLM, Courpron P, et al. The anabolic effect of human parathyroid hormone fragment (hPTH 1-34) therapy on trabecular bone in involutional osteoporosis: report of a multi-centre trial. Br Med J 1980;280:1340-4.
29. Mosekilde L, Reeve J. Treatment with PTH peptides. En: Marcus R, Feldman D, Kelsey J, editors. Osteoporosis. 2nd ed. Vol. 2. New York: Academic Press, 2001; p. 725-46.
30. Gardella TJ, Jüppner H, Bringhurst FR, Potts JT Jr. Receptors for parathyroid hormone (PTH) and PTH-related peptide. En: Bilezikian J, Raisz L, Rodan G, editors. Principles of bone biology. San Diego: Academic Press, 2002; p. 389-405.
31. Finkelstein JS. Pharmacological mechanisms of therapeutics: parathyroid hormone. En: Bilezikian JP, Raisz LG, Rodan GA, editors. Principles of bone biology. New York: Academic Press, 1996; p. 993-1005.
32. Liu BY, Guo J, Lanske B, Divieti P, Kronenberg HM, Bringhurst FR. Conditionally immortalized murine bone marrow stromal cells mediate parathyroid hormone-dependent osteoclastogenesis in vitro. Endocrinology 1998;139:1952-64.
33. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001;142:5050-5.
34. Aubin JE, Heersche JNM. Cellular actions of parathyroid hormone on osteoblast and osteoclast differentiation. En: Bilezikian JP, Marcus R, Levine MA, editors. The parathyroids, basic and clinical concepts. San Diego: Academic Press, 2001; p. 199-211.
35. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999;104:439-46.
36. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000;21:115-37.
37. Canalis E, Centrella M, Burch W, McCarthy TL. Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures. J Clin Invest 1989;83:60-5.
38. Dobnig H, Turner RT. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 1995;136:3632-8.
39. Jerome CP, Johnson CS, Vafai HT, Kaplan KC, Bailey J, Capwell B, et al. Effect of treatment for 6 months with human parathyroid hormone (1-34) peptide in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone 1999;25:301-9.
40. Kneissel M, Boyde A, Passer JA. Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathyroid hormone (PTH) analog SDZ PTS 893 or human PTH(1-34). Bone 2001;28:237-50.
41. Li M, Wronski TJ. Response of femoral neck to estrogen depletion and parathyroid hormone in aged rats. Bone 1995;16:551-7.
42. Thomsen JS, Mosekilde LI, Gasser JA. Long-term therapy of ovariectomy-induced osteopenia with parathyroid hormone analog SDZ PTS 893 and bone maintenance in retired breeder rats. Bone 1999;25:561-9.
43. Sato M, Zeng GQ, Turner CH. Biosynthetic human parathyroid hormone (1-34) effects on bone quality in aged ovariectomized rats. Endocrinology 1997;138:4330-7.
44. Hirano T, Burr DB, Turner CH, Sato M, Rick LC, Janet HM. Anabolic effects of human biosynthetic parathyroid hormone fragment (1-34), LY333334, on remodeling and mechanical properties of cortical bone in rabbits. J Bone Miner Res 1999;14:536-45.
45. Tam CS, Heersche JN, Murray TM, Parsons JA. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology 1982;10:506-12.
46. Rubin MR, Bilezikian JP. New anabolic therapies in osteoporosis. Endocrinol Metab Clin N Am 2003;32:285-307.
47. Neer RM, Amaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:434-41.
48. Marcus R, Wang OH, Satterwhite J, Mitlak B. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 2003;18:18-23.
49. Cosman F, Nieves J, Woelfert L, Formica C, Gordon S, Shen V, et al. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 2001;16:925-31.
50. Neer M, Slovik DM, Daly M, Potts T, Nussbaum SR. Treatment of postmenopausal osteoporosis with daily parathyroid hormone plus calcitriol. Osteoporos Int 1993;1:204-5.
51. Slovik DM, Rosenthal DI, Doppelt SH, Potts JT Jr, Daly M, Campbell JA, et al. Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxyvitamin. J Bone Miner Res 1986;1:377-81.
52. Hodsman AB, Fraher LJ, Watson PH, Ostbye T, Stitt LW, Adachi JD, et al. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 1997;82:620-8.
53. Reeve J, Mitchell A, Tellez M, Hulme P, Green JR, Wardley-Smith B, et al. Treatment with parathyroid peptides and estrogen replacement for severe post-menopausal vertebral osteoporosis: Long-term effects on spine and femur and determinants of magnitude of response. J Bone Miner Metab 2001;19:102-14.
54. Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, et al. Randomised controlled study of effect of parathyroid hormone on vertebral bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997;350:550-1.
55. Finkelstein JS, Klibanski A, Schaefer EH, Hornstein MD, Schiff I, Neer RM. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med 1994;331:1618-23.
56. Khosla S. Parathyroid hormone plus alendronate. A combination that does not add up. N Engl J Med 2003;349:1277-9.
57. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349:1207-15.
58. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. Effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003;349:1216-26.
59. Gasser JA. PTH and interactions with bisphosphonates. J Musculoskel Neuron Interact 2000;1:53-6.
60. Li M, Mosekilde L, Sogaard CH, Thomsen JS, Wronski TJ. Parathyroid hormone monotherapy and cotherapy with antiresorptive agents restore vertebral bone mass and strength in aged ovariectomized rats. Bone 1995;16:629-35.
61. Delmas PD, Vergnaud P, Arlot ME, Pastoureau P, Meunier PJ, Nilssen MHL. The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate. Is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? Bone 1995;6:603-10.
62. Greenspan SL, Emkey RD, Bone HG III. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of post-menopausal osteoporosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002;137:875-83.
63. Ettinger B, San Martin J, Crans GG, Pavo I. Response of markers of bone turnover and bone density to teriparatide in post-menopausal women previously treated with an antiresorptive drug. J Bone Miner Res 2003;18(Suppl 2):S15.
64. Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Millar PD, Peretz A, et al. A randomised double-blind trial to compare the efficacy of teriparatide (recombinant human parathyroid hormone 1-34) with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002;87:4528-35.
65. Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000;85:3069-76.
66. Orwoll E, Scheele W, Paul S, Adami S, Syversen U, Díez- Pérez A, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003;18:9-17.
67. Lane NE, Sánchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis: results of a randomised controlled clinical trial. J Clin Invest 1998;102:1627-33.
68. Eriksen EF, Lindsay R, Scheele WH, Clancy AD, Mitlak BH. Incident vertebral fractures during an 18-month observation period following discontinuation of recombinant human parathyroid hormone (1-34) use in postmenopausal women with osteoporosis. Osteoporos Int 2001;12(Suppl 2):S46.
69. Zanchetta JR, Rubio L, Mango A, Bogado CE. Changes in BMD at different skeletal sites after discontinuation of treatment with rhPTH (1-34) in postmenopausal osteoporotic women. J Bone Miner Res 2003;18(Suppl 2):S32.
70. Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 2000;85:2129-34.
71. Barbehenn EK, Lurie P, Wolfe SM. Osteosarcoma risk in rats using PTH1-34. Trends Endocrinol Metab 2001;12:383.
72. Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 2002;30:312-21.
73. Tashjian AH Jr, Chabner BA. Commentary on clinical safety of recombinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women. J Bone Miner Res 2002;17:1152-61.
74. Endocrinologic and metabolic drugs advisory comité. Disponible en: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3761b2_fda.htm
75. Marie PJ, Hott M, Modrowski D, De Pollak C, Guillemain J, Deloffre P, et al. An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res 1993;8:607-15.
76. Marie PJ, Ammann P, Boivin G, Rey C. Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int 2001;69:121-9.
77. Reginster JY, Deroisy R, Jupsin I. Strontium ranelate: a new paradigm in the treatment of osteoporosis. Drugs Today 2003;39:89-101.
78. Reginster JY, Meunier PJ. Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studies. Osteoporos Int 2003;14(Suppl 3):56-65.
79. Meunier PJ, Slosman DO, Delmas PD, Sebert JL, Brandi ML, Albanese C, et al. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis - A 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 2002;87:2060-6.
80. Reginster JY, Deroisy R, Dougados M, Jupsin I, Colette J, Roux C. Prevention of early postmenopausal bone loss by strontium ranelate: The randomized two year, double-masked, dose-ranging, placebo-controlled PREVOS trial: Osteoporos Int 2002;13:925-31.
81. Meunier PJ, Reginster JY. Design and methodology of the phase 3 trials for the clinical development of strontium ranelate in the treatment of women with postmenopausal osteoporosis. Osteoporos Int 2003;14(Suppl 3):S66-76.
82. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-68.
83. Reginster JY, Sawicki A, Devogelaer JP, Padrino JM, Kauffman JM, Doyle DV, et al. Strontium ranelate reduces the risk of hip fractures in women with postmenopausal osteoporosis. Osteoporos Int 2002;13(Suppl 3):S14.
84. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999;286:1946-9.
85. McFarlane SI, Muniyappa R, Francisco R, Sowers JR. Pleiotropic effects of statins: Lipid reduction and beyond. J Clin Endocrinol Metab 87:1451-8.
86. Bauer DC. HMG CoA reductase inhibitors and the skeleton: a comprehensive review. Osteoporos Int 2003;14:273-82.
87. Sugiyama M, Kodama T, Konishi K, Abe K, Asami S, Oikawa S. Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem Biophys Res Commun 2000;271:688-92.
88. Maritz FJ, Conradie MM, Hulley PA, Gopal R, Hough S. Effect of statins on bone mineral density and bone histomorphometry in rodents. Arterioscler Thromb Vasc Biol 2001;21:1636-41.
89. Rejnmark L, Buus NH, Verstergaard P, Heickendorff L, Andreasen F, Larsen ML, et al. Effects of simvastatin treatment in postmenopausal osteopenic women: a randomized controlled trial. J Bone Miner Res 2003;18(Suppl 2):S32.
90. Quesada JM, Montero J, Ruiz Roda R, Ruiz P, Cuenca R, Aguilera C, et al. Efecto de la atorvastatina sobre la densidad osea en mujeres postmenopáusicas hipercolesterolémicas. REEMO 2003;12(Supl 1):25.